Bruker (BRKR) Cut to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of Bruker (NASDAQ:BRKR) from a buy rating to a hold rating in a research note published on Tuesday morning, Zacks.com reports.

According to Zacks, “Bruker continues to witness strong year-over-year rise in organic revenues. We look forward to the company's Scientific Instruments segment that has been performing well driven by strong results from NANO and CALID groups. Bruker is progressing well with three strategic buyouts — majority interest in both Hain Diagnostics and Mestrelab along with Alicona Imaging acquisition. Further, it has made progress advancing proteomics and phenomics initiative with the rollout of timsTOF Pro and the gradual uptake of NMR phenomics. On the flip side, a competitive landscape and macroeconomic woes persistently pose challenges to the company. Growth within core BEST group was modest. Further, Bruker’s core BioSpin division faces fierce competition from companies offering magnetic resonance spectrometers. Through 2018, this business remained sluggish. Overall, Bruker underperformed the industry in the past six months.”

Several other brokerages have also weighed in on BRKR. Deutsche Bank raised shares of Bruker from a hold rating to a buy rating and raised their price objective for the company from $40.00 to $50.00 in a research report on Friday, April 12th. BidaskClub downgraded Bruker from a strong-buy rating to a buy rating in a report on Thursday, April 4th. BTIG Research reiterated a buy rating and set a $44.00 price target (up previously from $42.00) on shares of Bruker in a report on Tuesday, February 12th. ValuEngine upgraded Bruker from a hold rating to a buy rating in a report on Tuesday, January 15th. Finally, Needham & Company LLC began coverage on Bruker in a report on Wednesday, January 2nd. They set a strong-buy rating and a $39.00 price target on the stock. Two research analysts have rated the stock with a sell rating, two have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Bruker currently has an average rating of Hold and an average price target of $38.14.

Shares of BRKR opened at $38.92 on Tuesday. The company has a market cap of $6.20 billion, a P/E ratio of 27.80, a price-to-earnings-growth ratio of 2.18 and a beta of 1.47. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.33 and a current ratio of 2.18. Bruker has a twelve month low of $26.10 and a twelve month high of $40.25.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Monday, February 11th. The medical research company reported $0.54 earnings per share for the quarter, meeting the consensus estimate of $0.54. The firm had revenue of $553.60 million for the quarter, compared to analyst estimates of $544.53 million. Bruker had a net margin of 9.48% and a return on equity of 26.36%. Analysts predict that Bruker will post 1.57 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 22nd. Stockholders of record on Tuesday, March 5th were paid a $0.04 dividend. The ex-dividend date of this dividend was Monday, March 4th. This represents a $0.16 annualized dividend and a dividend yield of 0.41%. Bruker’s payout ratio is 11.43%.

Institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. grew its stake in shares of Bruker by 33.4% in the third quarter. JPMorgan Chase & Co. now owns 96,033 shares of the medical research company’s stock worth $3,213,000 after acquiring an additional 24,048 shares during the last quarter. Man Group plc grew its position in shares of Bruker by 120.0% during the 3rd quarter. Man Group plc now owns 461,627 shares of the medical research company’s stock worth $15,442,000 after buying an additional 251,764 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Bruker by 4.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,013,763 shares of the medical research company’s stock worth $30,178,000 after buying an additional 46,244 shares during the period. State Board of Administration of Florida Retirement System grew its position in shares of Bruker by 0.4% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 144,802 shares of the medical research company’s stock worth $4,311,000 after buying an additional 510 shares during the period. Finally, Rhumbline Advisers grew its position in shares of Bruker by 3.3% during the 4th quarter. Rhumbline Advisers now owns 102,048 shares of the medical research company’s stock worth $3,038,000 after buying an additional 3,254 shares during the period. Institutional investors and hedge funds own 68.89% of the company’s stock.

Bruker Company Profile

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Further Reading: Growth Stocks

Get a free copy of the Zacks research report on Bruker (BRKR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.